ATAI - Public offerings

– Co-Founder Maximilian Martin Appointed CEO – – Co-Founder Christian Angermayer Appointed Executive Chairman – – Jim Murren to join Board of Directors – – Company Appoints Sid Banthiya Chief Financial Officer; Promotes Alex Lopez to Chief Brand Officer and Rick Adams to Chief Sporting Officer – – Names Chris Jones Chief Communications Officer – NEW YORK, Nov. 19, 2025 /PRNewswire/ -- Enhanced, the elite sports competition and performance products company committed to giving athletes and people alike the ability to optimize their health, performance and recovery, today announced that it has fortified its executive leadership team and its board of directors.  Enhanced Fortifies Executive Lea

BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) Reported positive topline data from the Phase 2b open-label extension (OLE) study of BPL-003 showing the potential added and sustained antidepressant effects following a second dose in patients with TRD Reported positive open-label Phase 2a data demonstrating improved outcomes with a two-dose induction regimen of BPL-003 in patients with TRDAn End-of-Phase 2 meeting is scheduled with the FDA for BPL-003, anticipate providing guidance on the Phase 3 clinical program in the first quarter of 2026Completed enrollment in the ex

atai Life Sciences' shareholders voted to approve the strategic combination with Beckley Psytech Limited and the corporate redomiciliation at the Extraordinary General Meeting of Shareholders on November 4, 2025, with approximately 98% of the votes cast at the Extraordinary General Meeting in favor of the transactionsAtaiBeckley has an industry-leading pipeline of investigational treatments, led by BPL-003 (mebufotenin benzoate nasal spray), a Phase 3-ready asset Diversified portfolio also includes Phase 2 assets VLS-01 (DMT buccal film) and EMP-01 (oral R-MDMA), as well as a portfolio of novel 5-HT2A receptor agonists, including non-hallucinogenic neuroplastogens, in preclinical development

NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on October 20, 2025, the closing of its public offering of 27,283,750 common shares occurred, inclusive of the closing of the underwriters' option in full to purchase an additional 3,558,750 common shares at the public offering price of $5.48 per share following the exercise by the underwriters of their option on October 17, 2025. The aggregate gross proceeds from the offering, including the gross proceeds from the exercise of the underwriters' option to purchas

NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 23,725,000 common shares, at a price of $5.48 per share. atai has granted the underwriters a 30-day option to purchase up to an additional 3,558,750 common shares at the public offering price, less the underwriting discount. All common shares to be sold in the offering will be sold by atai. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering ex

NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of its common shares. atai expects to grant the underwriters a 30-day option to purchase additional common shares at the public offering price, less the underwriting discount. All common shares to be sold in the offering will be sold by atai. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or a

NEW YORK and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on February 14, 2025, the closing of its public offering of 26,190,477 common shares occurred. Additionally, on February 17, 2025, the underwriter exercised its option in full to purchase an additional 3,928,571 common shares at the public offering price of $2.10 per share, and the closing of the underwriter's option to purchase 3,928,571 additional common shares occurred on February 19, 2025. The aggregate gross proceeds from the offering, including t

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 26,190,477 common shares, at a price of $2.10 per share. atai has granted the underwriter a 30-day option to purchase up to an additional 3,928,571 common shares. All common shares to be sold in the offering will be sold by atai. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by atai, are expected to be approximately $55 mi

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of $55,000,000 of its common shares. atai expects to grant the underwriter a 30-day option to purchase up to an additional $8,250,000 of common shares. All common shares to be sold in the offering will be sold by atai. atai intends to use the net proceeds from this offering for general corporate purposes, including for working capital and to advance the clinical development of its product candi

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), effective immediately. Mr. Weaver will lead the Company's finance and accounting functions, including SEC reporting and investor relations. "We are pleased to welcome Greg to Altimmune's executive team during such a pivotal time in our evolution. He has a wealth of experience that we believe will be invaluable as we enter a crucial period in the development of our lead program, pemvidutide and in our advancement as an organization," said Vipin K. Garg, Ph.D., President and Chief Execu

Rezolve has entered into a definitive business combination agreement with Cohen & Company backed Armada Acquisition Corp. I (NASDAQ:AACI)Deal positions Rezolve as a leader of Mobile Commerce transformation globallyPowerful partner driven business model positions Rezolve to quickly capitalize on very large market opportunityThe transaction is expected to result in $190 million in gross proceeds, including $150 million in trust (assuming no redemptions) and approximately $40 million of additional capital from Christian Angermayer and Betsy Cohen $2 billion pro forma combined company market capitalization represents a significant valuation discount relative to public market peers This press re

NEW YORK and BERLIN, Oct. 19, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company, today announced the launch of its new philanthropic program, atai Impact, in line with atai Life Sciences' vision, to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. atai Impact has been developed to harness the power of innovative mental health approaches for positive social change, committed to advancing education, expanding access and supporting the wider ecosystem. Its establishment is based on atai Life Sciences' position that, while a for-profit model is the swiftest and most robust means of unlocking

-Successfully completed Initial Public Offering on Nasdaq raising $258.8 million in gross proceeds, including the underwriters' over-allotment- -Received $20 million upfront payment from Otsuka as part of the first major collaboration between a biopharmaceutical company developing psychedelics and large pharma- -Advancement of 11 therapeutic programs, including initiation of Recognify's Phase 2 and GABA's Phase 1 trials- -18 significant catalysts across atai's platform anticipated over next 18 months including two clinical trials to be completed and four clinical trials to be initiated in 2021- -Solidified leadership position with strong cash position of $453.6 million to advance our cu